Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 2,000.00
spinner
Single User $ 3,000.00
spinner
Multiple User $ 4,000.00
spinner
Corporate User $ 6,000.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Acute Myeloid Leukemia Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 

Available formats:    

StumbleUponEmail

Acute Myeloid Leukemia Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Acute Myeloid Leukemia Pipeline Drugs Assessment

 

Overview:

Acute myeloid leukemia is a type of blood cancer,affects white blood cells. It enables progress rapidly, requires immediate treatment. Acute myeloid leukemia symptoms develop over a few weeks and become increasingly more severe. Symptoms may include tiredness, pale skin, breathlessness and unusual & frequent bleeding.

If symptoms are persisted, diagnostic tests may include blood tests, bone marrow test, lumbar puncture and sometimes genomic testing may be suggested. There is no specific cure available for acute myeloid leukemia. But it is treated by the combination of therapies that include chemotherapeutic agents, stem cell transplantation, radiation therapy and targeted therapy.

 

Segmentation:

Acute myeloid leukemia pipeline drugs are segmented based onroute of administration, trial phase,and company

By Route of Administration, acute myeloid leukemia pipeline drugs are segmented into

  • Oral
  • Parenteral
  • Others

By Trial Phase, Acute Myeloid Leukemia pipeline drugs are segmented into

  • Pre-clinical phase
  • Phase-I
  • Phase II
  • Phase-III

By Company, Acute Myeloid Leukemia pipeline drugs are segmented into

  • Cyclacel Pharmaceuticals Inc. (U.S.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • H. BoehringerSohn AG &Ko. KG (Germany)

 

Space Analysis:

Many of the drugs and treatments are being developed under the clinical trials for the treatment of acute myeloid leukemia. Companies are looking for the most effective chemotherapy drugs while still avoiding the side effects. Some of the chemotherapeutics drugs under clinical trials include sapacitabine, tipifarnib,andbortezomib.  Furthermore, immunotherapies and stem cell therapies also effectively studying by the researchers to treat the acute myeloid leukemia. In addition, targeted therapy class of drugs such as FLT3 Inhibitors, Histone deacetylase inhibitors,and aurora kinase inhibitors are the promising for the treatment of acute leukemia.

  • In October 2017, U.S. Food and Drug Administration granted fast-track designation for development of gilteritinib for adult patients with FLT3 mutation positive relapsed or refractory acute myeloid leukemia.

 

Report Description:

Acute Myeloid Leukemia Pipeline Drugs Assessment report studies the various therapeutics under clinical development for uterine fibroids treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the uterine fibroids pipeline drugsdevelopment. This report studies the dynamics of the Acute Myeloid Leukemia Pipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on uterine fibroids pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis of each drug candidates in the clinical trial phases
  • Cyclacel Pharmaceuticals Inc. (U.S.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • H. BoehringerSohn AG &Ko. KG (Germany)

1. Executive Summary

 

2. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Introduction

 

2.1. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market – Taxonomy

2.2. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market –Definitions

2.2.1. Route of Administration

2.2.2. Trail Phase

 

3. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamic Factors – Impact Analysis

3.6. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market – Competition Landscape

3.7. Epidemiology

 

4. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024

4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market opportunity analysis

 

5. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1. Oral

5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

 

5.2. Parenteral

5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

 

5.3. Others

5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

 

6. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market, By Trial Phase, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1. Pre-clinical phase

6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

 

6.2. Phase-I

6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

 

6.3. Phase II

6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

 

6.4. Phase-III

6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.4.3. Market Opportunity Analysis

 

7. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1. North America

7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

 

7.2. Europe

7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

 

7.3. Asia-Pacific

7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

 

7.4. Latin America

7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

 

7.5. Middle East and Africa

7.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.5.3. Market Opportunity Analysis

7.6. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024

 

8. North America Acute Myeloid Leukemia Pipeline Drugs Assessment MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

8.1.1. Oral

8.1.2. Parenteral

8.1.3. Others

 

8.2. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.2.1. Pre-clinical phase

8.2.2. Phase-I

8.2.3. Phase II

8.2.4. Phase-III

 

8.3. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

8.3.1. U.S.

8.3.2. Canada

8.4. North America Acute Myeloid Leukemia Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024

8.5. North America Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics – Trends

 

9. Europe Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.1. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

9.1.1. Oral

9.1.2. Parenteral

9.1.3. Others

 

9.2. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Pre-clinical phase

9.2.2. Phase-I

9.2.3. Phase II

9.2.4. Phase-III

 

9.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.3.1. Germany

9.3.2. UK

9.3.3. France

9.3.4. Spain

9.3.5. Italy

9.3.6. Russia

9.3.7. Poland

9.3.8. Rest of Europe

 

9.4. Europe Acute Myeloid Leukemia Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024

9.5. Europe Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics – Trends

 

10. Asia-Pacific Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

10.1. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Oral

10.1.2. Parenteral

10.1.3. Others

 

10.2. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Pre-clinical phase

10.2.2. Phase-I

10.2.3. Phase II

10.2.4. Phase-III

 

10.3. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)       

10.3.1. Japan

10.3.2. China

10.3.3. India

10.3.4. ASEAN

10.3.5. Australia & New Zealand

10.3.6. Rest of Asia-Pacific

 

10.4. Asia-Pacific Acute Myeloid Leukemia Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024

10.5. Asia-Pacific Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics – Trends

 

11. Latin America Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

11.1. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Oral

11.1.2. Parenteral

11.1.3. Others

 

11.2. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Pre-clinical phase

11.2.2. Phase-I

11.2.3. Phase II

11.2.4. Phase-III

 

11.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.3.1. Brazil

11.3.2. Mexico

11.3.3. Argentina

11.3.4. Venezuela

11.3.5. Rest of Latin America

 

11.4. Latin America Acute Myeloid Leukemia Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024

11.5. Latin America Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics – Trends

 

12. Middle East and Africa Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

12.1. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Oral

12.1.2. Parenteral

12.1.3. Others

 

12.2. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Pre-clinical phase

12.2.2. Phase-I

12.2.3. Phase II

12.2.4. Phase-III

 

12.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.3.1. Gulf Cooperation Council (GCC) Countries

12.3.2. Israel

12.3.3. South Africa

12.3.4. Rest of MEA

 

12.4. MEA Acute Myeloid Leukemia Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024

12.5. MEA Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics – Trends

 

13. Competition Landscape

13.1. Strategic Dashboard of Top Market Players

13.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

13.2.1. Cyclacel Pharmaceuticals Inc. (U.S.)

13.2.2. Johnson & Johnson Services, Inc. (U.S.)

13.2.3. Novartis AG (Switzerland)

13.2.4. H. BoehringerSohn AG &Ko. KG (Germany)

 

14. Research Methodology

15. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553